ArticleEuropean journal of nuclear medicine and molecular imaging2026
A deep learning PET/CT biomarker for early progression (POD24) and survival stratification in follicular lymphoma: a multicenter study.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo develop and validate a prognostic imaging biomarker derived from baseline [¹⁸F]FDG PET/CT using tabular deep learning for prediction of progression of disease within 24 months (POD24) and survival risk stratification in patients with follicular lymphoma (FL).
methodsThis retrospective multicenter study included 309 patients with newly diagnosed FL (grades 1-3a) from five independent medical centers. Tumor volumes segmented from baseline [¹⁸F]FDG PET and CT images were used to extract high-throughput radiomic features. Five conventional machine learning algorithms and four advanced tabular deep learning models were developed and compared. The predictive output of the GAMformer model was defined as the deep learning score (DLS). The DLS was integrated with clinical variables and PET metabolic parameters to construct a multiparametric model in the training cohort. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis, and further validated in validation cohort.
resultsDuring a median follow-up of 44 months, POD24 occurred in 55 patients. The DLS demonstrated strong predictive performance for POD24 (training AUC = 0.857; validation AUC = 0.753). The multiparametric model further improved discrimination, achieving AUCs of 0.882 in the training cohort and 0.797 in the validation cohort, outperforming FLIPI, FLIPI-2, and PRIMA-PI. Calibration showed good agreement, and decision curve analysis indicated higher net clinical benefit. The DLS stratified survival risk (P < 0.05) and remained predictive of survival and POD24 across histologic grades.
conclusionsThe DLS derived from baseline [¹⁸F]FDG PET/CT enables POD24 prediction and accurate survival risk stratification in FL, supporting its potential role in precision management.
Indexed as
Identifiers
41870550What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.